CTIS2023-509227-41-00进行中（未招募）1 期
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in patients with low risk localized gastroesophageal adenocarcinoma (study PRODIGE/FRENCH 39) - ET23-350
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •I1.Age = 18 years, I10.Signed and dated informed consent for prior to any study-specific procedure, I11.Women of childbearing potential accepting to use highly effective contraceptive measures or abstain from heterosexual activity, for the course of the study and at least an- 9 months after the end of the treatment with oxaliplatin - 6 months after the end of the treatment with fluorouracil - 2 months after the end of the treatment with docetaxel and men must use contraception during treatment and at least - 6 months after the end of the treatment with oxaliplatin, - 3 months after the end of the treatment with fluorouracil - 4 months after the end of the treatment with docetaxel., I12.Patient must be covered by a medical insurance or equivalent, I2.Histologically proven non-metastatic (M0) gastric, esophageal or gastroesophageal junction adenocarcinoma, I3.Subjects must have completed both pre-operative chemotherapy with a fluoropyrimidine-platinum containing regimen (FLOT 4 cycles) and microscopically complete (R0) resection prior to randomization. Note for surgery: total or distal gastrectomy with D2 lymphadenectomy according to ESMO guidelines should have been completed for gastric and junctional Siewert type III cancers. Ivor Lewis oesophagectomy with two field lymphadenectomy should have been performed for junctional Siewert type I cancers and lower esophageal adenocarcinomas. For Siewert type II cancers either total gastrectomy with D2-lymphadenectomy or oesophagectomy with two field lymphadenectomy should have been completed. Open, minimal invasive or hybrid surgical approaches are acceptable as long as the requirements above are fulfilled. In frail patients with Siewert I or II, transhiatal oesophagectomy with lymphadenectomy in the lower mediastinum without transthoracic access is acceptable. Regardless of the type of surgery a minimum of 16 (gastric cancer) or 7 lymph nodes (in case of esophageal carcinoma) should have been resected and examined (ref TNM 8 eme edition, I4.Low risk of disease recurrence, defined by the following criteria: -Absence of lymph node involvement (ypN0), assessed on a min. of 16 or 7 lymph nodes according to the localization and, -Either ypT0-2 (all TRG grade) or ypT3 (with TRG 1a-b according to Becker classification or TRG1-2 according to Mandard’s classification),, I5.ECOG Performance Status 0-1, I6.Patients fit to receive post-operative chemotherapy, I7.Interval between the date of surgery and the date of randomization no longer than 10 weeks, I8.Adequate organs function (ranges defined in the clinical trial protocol), I9.No contraindication to study assessments,
排除标准
- •E1.Oesophageal squamous cell carcinomas, E10.Suspicion of serious infection, E11.Pregnant or breastfeeding woman, E12.Patient under tutorship or curatorship of deprived of liberty., E2.Tumor with Deficient MisMatch Repair (MMR) and/or Microsatellite Instability status, E3.Dihydro Pyrimidine Dehydrogenase (DPD) deficiency, NB: if not previously done, the following blood chemistry level must be perform at screening, : blood uracil level - uracilemia dosing result is mandatory prior the inclusion, E4.Persistent toxicities related to prior treatment of grade>1,, E5.QTcF longer than 450 msec for men and longer than 470 msec for women,, E6.Hypokalemia OR Hypomagnesemia OR Hypocalcemia Grade>1, E7.Contraindication to postoperative treatment (FLOT): •Known history of hypersensitivity to fluorouracil, oxaliplatin, docetaxel or calcium folinate to any of their excipients, according to the SmPCs of these products OR •Peripheral sensory neuropathy with functional impairment prior to first treatment according the SmPC of oxaliplatin OR •Clinically significant active heart disease or myocardial infarction within 6 months OR • •Recent or concomitant treatment with brivudine or recent treatment with live vaccines (minimal wash out period before randomisation: 4 weeks), E8.Any concurrent chemotherapy, Investigational product for cancer treatment., E9.Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study
研究者
相似试验
进行中（未招募）
1 期
A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients. - GBG 54 - MALEBreast Cancer in Male PatientsMedDRA version: 19.0Level: PTClassification code 10061020Term: Breast cancer maleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015122-11-DEGBG Forschungs GmbH48
进行中（未招募）
1 期
A prospective phase II, randomized multi-center trial of a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squamous cell lung cancer and non- squamous cell lung cancer, respectively after platin failure (ModuLung)EUCTR2014-004095-31-DEFreistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor86
终止
2 期
A Prospective multicentre, phase 2b randomised controlled double-blind trial, to determine the safety and efficacy of perispinal etanercept on quality of life at 28 days post treatmentACTRN12620001011976The Florey Institute of Neuroscience and Mental Health126
进行中（未招募）
1 期
A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19)EUCTR2020-002027-10-SEorrlands universitetssjukhus600
Unknown
2 期
Safety, Tolerability andImmunogenicity of the candidate GEMCOVAC-19 (COVID-19vaccine) in healthy pediatric subjects of 5 to less than 18 yearsCTRI/2022/04/041880Gennova Biopharmaceuticals Limited